Kaleen Konrad Childers

This inventor holds 13 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 10 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Merck Canada Inc., Merck Sharp & Dohme LLC. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kaleen Konrad Childers. Retrieved from https://idiyas.com/inventor/kaleen-konrad-childers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 2)

% Patents Active = 92.3

CIPO Patents = 1

EPO Patents = 10 (Patent Applications = 10)

Average Co-Inventor Count = 10.4

ph-index = 7

Forward Citations = 95(Granted Patents)

Location History:

Newton, MA (US) (2013 - 2017)
Medfield, MA (US) (2016 - 2017)

Company Filing History:

12 out of 2,405

Merck Sharp + Dohme Corp.

Merck Sharp & Dohme LLC

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760026 - Heteroaroyl amides as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2026-10-13),

2. 9745295 - Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors (2017-08-29),

3. 9598405 - Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors (2017-03-21),

4. 9586931 - Triazolyl derivatives as Syk inhibitors (2017-03-07),

5. 9487504 - Imidazolyl analogs as syk inhibitors (2016-11-08),

6. 9416111 - Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors (2016-08-16),

7. 9290490 - Aminopyrimidines as Syk inhibitors (2016-03-22),

8. 9242984 - Pyrazolyl derivatives as Syk inhibitors (2016-01-26),

9. 9216173 - 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors (2015-12-22),

10. 9120785 - Pyridyl aminopyridines as Syk inhibitors (2015-09-01),

11. 8987456 - 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors (2015-03-24),

12. 8759366 - Aminopyrimidines as SYK inhibitors (2014-06-24),

13. 8551984 - Aminopyrimidines as SYK inhibitors (2013-10-08),

Title: Celebrating the Innovations of Kaleen Konrad Childers

Introduction: Kaleen Konrad Childers, based in Newton, MA, is a distinguished inventor known for her significant contributions to the field of pharmaceutical sciences. With a robust portfolio of 12 patents, Childers has made remarkable strides in developing innovative compounds aimed at treating diseases mediated by Spleen Tyrosine Kinase (Syk).

Latest Patents: Among her latest innovations, two notable patents stand out. The first is titled "Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors." This invention provides thiazole-substituted aminoheteroaryl compounds and their pharmaceutically acceptable salts, along with pharmaceutical compositions derived from these compounds. The methods outlined in this patent focus on using these innovative compounds for treating conditions related to Spleen Tyrosine Kinase (Syk).

Her second noteworthy patent is "Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors." It features thiazole-substituted aminopyridine compounds and their pharmaceutically acceptable salts, designed for similar therapeutic applications. Together, these patents exemplify Childers' commitment to advancing medical treatments targeting Syk-related diseases.

Career Highlights: Childers has had an impressive career, prominently featuring her tenure at Merck Sharp & Dohme Corporation and Merck Canada Inc. These companies have been instrumental in supporting her research and development efforts, providing a platform for her innovative ideas to flourish.

Collaborations: Throughout her career, Childers has collaborated with notable scientific professionals including Alan B. Northrup and Michael D. Altman. These collaborations have enriched her research endeavors, allowing for a multidisciplinary approach to her inventions.

Conclusion: Kaleen Konrad Childers exemplifies the spirit of innovation in the pharmaceutical industry. Through her extensive patent portfolio and collaborations with leading scientists, she continues to contribute to significant advancements in medical treatments. Her work not only reflects her inventive prowess but also illustrates the vital role of inventors in shaping a healthier future.

Profile summary based on public USPTO records.